---
_id: '13232'
abstract:
- lang: eng
  text: The potential of immune-evasive mutation accumulation in the SARS-CoV-2 virus
    has led to its rapid spread, causing over 600 million confirmed cases and more
    than 6.5 million confirmed deaths. The huge demand for the rapid development and
    deployment of low-cost and effective vaccines against emerging variants has renewed
    interest in DNA vaccine technology. Here, we report the rapid generation and immunological
    evaluation of novel DNA vaccine candidates against the Wuhan-Hu-1 and Omicron
    variants based on the RBD protein fused with the Potato virus X coat protein (PVXCP).
    The delivery of DNA vaccines using electroporation in a two-dose regimen induced
    high-antibody titers and profound cellular responses in mice. The antibody titers
    induced against the Omicron variant of the vaccine were sufficient for effective
    protection against both Omicron and Wuhan-Hu-1 virus infections. The PVXCP protein
    in the vaccine construct shifted the immune response to the favorable Th1-like
    type and provided the oligomerization of RBD-PVXCP protein. Naked DNA delivery
    by needle-free injection allowed us to achieve antibody titers comparable with
    mRNA-LNP delivery in rabbits. These data identify the RBD-PVXCP DNA vaccine platform
    as a promising solution for robust and effective SARS-CoV-2 protection, supporting
    further translational study.
acknowledgement: The authors declare that this study received funding from Immunofusion.
  The funder was not involved in the study design, collection, analysis, interpretation
  of data, the writing of this article, or the decision to submit it for publication.
  The authors express their gratitude to the Institute of Physiology of the National
  Academy of Sciences of Belarus for providing assistance in keeping laboratory animals.
article_number: '1014'
article_processing_charge: No
article_type: original
author:
- first_name: Dmitri
  full_name: Dormeshkin, Dmitri
  last_name: Dormeshkin
- first_name: Mikalai
  full_name: Katsin, Mikalai
  last_name: Katsin
- first_name: Maria
  full_name: Stegantseva, Maria
  last_name: Stegantseva
- first_name: Sergey
  full_name: Golenchenko, Sergey
  last_name: Golenchenko
- first_name: Michail
  full_name: Shapira, Michail
  last_name: Shapira
- first_name: Simon
  full_name: Dubovik, Simon
  last_name: Dubovik
- first_name: Dzmitry
  full_name: Lutskovich, Dzmitry
  last_name: Lutskovich
- first_name: Anton
  full_name: Kavaleuski, Anton
  id: 62304f89-eb97-11eb-a6c2-8903dd183976
  last_name: Kavaleuski
  orcid: 0000-0003-2091-526X
- first_name: Alexander
  full_name: Meleshko, Alexander
  last_name: Meleshko
citation:
  ama: Dormeshkin D, Katsin M, Stegantseva M, et al. Design and immunogenicity of
    SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. 2023;11(6).
    doi:<a href="https://doi.org/10.3390/vaccines11061014">10.3390/vaccines11061014</a>
  apa: Dormeshkin, D., Katsin, M., Stegantseva, M., Golenchenko, S., Shapira, M.,
    Dubovik, S., … Meleshko, A. (2023). Design and immunogenicity of SARS-CoV-2 DNA
    vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. MDPI. <a href="https://doi.org/10.3390/vaccines11061014">https://doi.org/10.3390/vaccines11061014</a>
  chicago: Dormeshkin, Dmitri, Mikalai Katsin, Maria Stegantseva, Sergey Golenchenko,
    Michail Shapira, Simon Dubovik, Dzmitry Lutskovich, Anton Kavaleuski, and Alexander
    Meleshko. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP
    Fusion Protein.” <i>Vaccines</i>. MDPI, 2023. <a href="https://doi.org/10.3390/vaccines11061014">https://doi.org/10.3390/vaccines11061014</a>.
  ieee: D. Dormeshkin <i>et al.</i>, “Design and immunogenicity of SARS-CoV-2 DNA
    vaccine encoding RBD-PVXCP fusion protein,” <i>Vaccines</i>, vol. 11, no. 6. MDPI,
    2023.
  ista: Dormeshkin D, Katsin M, Stegantseva M, Golenchenko S, Shapira M, Dubovik S,
    Lutskovich D, Kavaleuski A, Meleshko A. 2023. Design and immunogenicity of SARS-CoV-2
    DNA vaccine encoding RBD-PVXCP fusion protein. Vaccines. 11(6), 1014.
  mla: Dormeshkin, Dmitri, et al. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine
    Encoding RBD-PVXCP Fusion Protein.” <i>Vaccines</i>, vol. 11, no. 6, 1014, MDPI,
    2023, doi:<a href="https://doi.org/10.3390/vaccines11061014">10.3390/vaccines11061014</a>.
  short: D. Dormeshkin, M. Katsin, M. Stegantseva, S. Golenchenko, M. Shapira, S.
    Dubovik, D. Lutskovich, A. Kavaleuski, A. Meleshko, Vaccines 11 (2023).
date_created: 2023-07-16T22:01:10Z
date_published: 2023-06-01T00:00:00Z
date_updated: 2023-08-02T06:31:19Z
day: '01'
ddc:
- '570'
department:
- _id: LeSa
doi: 10.3390/vaccines11061014
external_id:
  isi:
  - '001017740000001'
file:
- access_level: open_access
  checksum: 8f484c0f30f8699c589b1c29a0fd7d7f
  content_type: application/pdf
  creator: dernst
  date_created: 2023-07-18T07:25:43Z
  date_updated: 2023-07-18T07:25:43Z
  file_id: '13244'
  file_name: 2023_Vaccines_Dormeshkin.pdf
  file_size: 2339746
  relation: main_file
  success: 1
file_date_updated: 2023-07-18T07:25:43Z
has_accepted_license: '1'
intvolume: '        11'
isi: 1
issue: '6'
language:
- iso: eng
month: '06'
oa: 1
oa_version: Published Version
publication: Vaccines
publication_identifier:
  eissn:
  - 2076-393X
publication_status: published
publisher: MDPI
quality_controlled: '1'
scopus_import: '1'
status: public
title: Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion
  protein
tmp:
  image: /images/cc_by.png
  legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
  name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
  short: CC BY (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 11
year: '2023'
...